Genome & Company

A314130

KR7314130006

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
6,910 ^KRW	+2.98%		-1.71%	-44.68%

Jan. 24	Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	CI
2023	Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	CI

Genome & Company announced that it has received KRW 27.20018096 billion in funding from Tyel Asset Management Co,. Ltd., Smilegate Investment, Inc. and other investors

August 22, 2019

On August 23, 2019, Genome & Company (XKON:A314130) closed the transaction.

Latest news about Genome & Company

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	Jan. 24	CI
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	23-05-19	CI
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors	23-04-06	CI
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors	23-04-04	CI
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors	22-09-01	CI
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors	22-08-17	CI
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc	22-03-03	CI
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse	21-09-21	CI
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	21-09-20	CI
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.	21-09-07	CI
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study	21-03-09	CI
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients	21-02-24	CI
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001	20-10-27	CI
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm	20-08-25	CI
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors	20-08-10	CI
Scioto Biosciences, Inc. announced that it expects to receive $6.50074 million in funding	20-08-06	CI
Genome & Company announced that it has received KRW 4.00002 billion in funding	20-06-24	CI
Genome & Company announced that it expects to receive KRW 4.00002 billion in funding	20-06-16	CI
Genome & Company announced that it has received KRW 3.62991 billion in funding	20-04-23	CI
Genome & Company Receives FDA IND Clearance for GEN-001, its First Anti-Cancer Microbiome Therapeutic	20-04-20	CI
Genome & Company announced that it expects to receive KRW 3.62991 billion in funding	20-04-15	CI
Genome & Co to Raise USD 3 Million in Private Placement	20-04-15	CI
Genome & Company Announces A Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer Inc	20-01-13	CI
Genome & Company announced that it has received KRW 27.20018096 billion in funding from Tyel Asset Management Co,. Ltd., Smilegate Investment, Inc. and other investors	19-08-22	CI
Genome & Company announced that it has received KRW 2.99999184 billion in funding from Korea Investment & Securities Co., Ltd.	19-08-22	CI

Genome&Company is a company mainly engaged in the research, development, manufacturing and sale of probiotics. Probiotics are mainly used in products including immune oncology therapeutic supplements, dietary supplements, cosmetics and medicines. These products are mainly applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENOME & COMPANY	-44.68%	73.04M
IQVIA HOLDINGS INC.	+0.40%	42.86B
MODERNA, INC.	+11.90%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.56%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-24.01%	18.63B
MEDPACE HOLDINGS, INC.	+27.52%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.75%	11.92B
UNITED THERAPEUTICS CORPORATION	+7.21%	11.21B